Irbesartan-mediated AT receptor blockade attenuates hyposmotic-induced enhancement of current and prevents shortening of action potential duration in atrial myocytes

Introduction: Stretch of the atrial membrane upregulates the slow component of delayed rectifier K + current ( I Ks ). Blockade of angiotensin II subtype 1 receptors (AT 1 R) attenuates this increase in I Ks . The present study aimed to examine the effects of irbesartan, a selective AT 1 R blocker (...

Full description

Bibliographic Details
Main Authors: Jie Wu, Wei-Guang Ding, Jin Zhao, Wei-Jin Zang, Hiroshi Matsuura, Minoru Horie
Format: Article
Language:English
Published: SAGE Publications 2014-12-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.1177/1470320312474855
Description
Summary:Introduction: Stretch of the atrial membrane upregulates the slow component of delayed rectifier K + current ( I Ks ). Blockade of angiotensin II subtype 1 receptors (AT 1 R) attenuates this increase in I Ks . The present study aimed to examine the effects of irbesartan, a selective AT 1 R blocker (ABR), on both the enhancement of I Ks and the shortening of action potential duration (APD) induced by stretching atrial myocytes for exploring the mechanisms underlying the prevention of atrial fibrillation (AF) by ABR. Methods: Hyposmotic solution (Hypo-S) was used to stretch guinea pig atrial myocytes. I Ks and APD were recorded using the whole-cell patch-clamp technique. Results: Irbesartan (1–50 μM) attenuated the Hypo-S-induced increase in I Ks and shortening of APD 90 . Hypo-S increased the I Ks by 113.4%, whereas Hypo-S + 1 μM irbesartan and Hypo-S + 50 μM irbesartan increased the I Ks by only 74.5% and 70.3%, respectively. In addition, Hypo-S shortened the APD 90 by 19.0%, whereas Hypo-S + 1 μM irbesartan and Hypo-S + 50 μM irbesartan shortened the APD 90 by 12.1% and 12.0%, respectively. Conclusion: The actions of irbesartan on electrical changes induced by stretching atrial myocytes are associated with blocking AT 1 R. These actions may be beneficial for treating AF.
ISSN:1470-3203
1752-8976